



BIOSENSORS
INTERNATIONAL

NEWS RELEASE

**Biosensors Completes US\$15 Million Final Tranche of
US\$45 Million Convertible Note Financing**

Singapore, 5 January 2007 – Biosensors International Group, Ltd. (“Biosensors” or the “Company”, Bloomberg BIG SP) announced today that it has completed its convertible note financing, previously announced on 23 November 2006, with the closing of the third and final tranche in the amount of US\$15 million and the issuance of convertible and unsubordinated 3.95% three-year notes. The closing of this final tranche, placed with Silicon Valley-based Three Arch Partners, increases the total raised in the financing to US\$45 million.

Three Arch Partners, based in Portola Valley, California, is one of the pre-eminent healthcare investment companies in the United States having made more than US\$1 billion in venture, development and growth stage investments in more than eighty medical technology companies since its inception in 1993.

Mr. Yoh-Chie Lu, Chairman and CEO of Biosensors commented: “This successful financing is an important milestone for Biosensors as we prepare for the launch of our flagship BioMatrix® drug-eluting stent as well as accelerate our other ongoing research and development programs.

Participants in the financing include Granite Global, Evolution Capital and now Three Arch Partners which specialize in investments in healthcare and medical technology in the US. Three Arch Partners is a premier name in the private equity business with a strong track record of providing healthcare companies with access to relevant clinical, business and capital resources”.

Mr. Lu added, “I have also submitted the name of Mr. Mark Wan, the founding partner of Three Arch Partners, for consideration by the nomination committee to invite him to serve as a director on Biosensors’ Board. Mr. Wan’s extensive experience and knowledge of the healthcare industry would further enrich the Board’s expertise in defining management strategies and attaining corporate objectives.”

Mr. Mark Wan of Three Arch Partners commented: "Biosensors has the technology and the opportunity to become a technology leader in the drug-eluting stent market, as its technologies continue to receive strong validation by leading cardiologists. The Company’s technological achievements in developing polymer-free and biodegradable stent platforms underlies its prospects to emerge as a key player in this US\$6 billion drug-eluting stent market. Three Arch Partners is very pleased to be a part of this exciting company and I look forward to be able to lend my expertise and the resources of our organization where possible.”

Details of the issuance of the convertible notes to Three Arch Partners are separately announced in the Company’s filing with the Singapore Stock Exchange dated 5 January 2007.

##End of Release##

Media Contact

Biosensors International Group

Ms Tina Lim, Executive, Corporate Communications

Tel : (65) 6213 5712

Email : media@biosensors.com

Media Relations / Investor Relations Firm

United States

Allen & Caron Inc.

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary antirestenotic drug. It is pursuing three separate drug-eluting stent programs, *BioMatrix*[®], *Axxion*[™], and *BioMatrix*[®] *Freedom*[™], a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

About Three Arch Partners

Three Arch Partners was formed in 1993 to provide young companies with access to relevant clinical and business resources, as well as capital. Three Arch Partners has helped create, build, and fund more than eighty healthcare companies. The investment focus is on opportunities in medical devices and healthcare services, as well as biotechnology and information technology. The partnership manages over \$1 billion in capital.

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.